Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States

References

• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Barbui T, Cervantes F, et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v85–99.
   PubMed Web of Science ®Google Scholar
• Hultcrantz M, Bjorkholm M, Dickman PW, et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med. 2018;168(5):317–325.
   PubMed Web of Science ®Google Scholar
• Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224–2232.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly-annotated essential thrombocythemia, polycythemia vera and myelofibrosis. Blood. 2014;124(16):2507–2513.
   PubMed Web of Science ®Google Scholar
• Price GL, Davis KL, Karve S, et al. Survival patterns in United States (US) Medicare enrollees with non-CML myeloproliferative neoplasms (MPN). PLoS One. 2014;9(3):e90299.
   PubMed Web of Science ®Google Scholar
• Hultcrantz M, Kristinsson SY, Andersson TM, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012;30(24):2995–3001.
   PubMed Web of Science ®Google Scholar
• Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098–4103.
   PubMed Web of Science ®Google Scholar
• Mesa R, Miller CB, Thyne M, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey. BMC Cancer. 2016;16:167.
   PubMed Web of Science ®Google Scholar
• Moulard O, Mehta J, Fryzek J, et al. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014;92(4):289–297.
   PubMed Web of Science ®Google Scholar
• Titmarsh GJ, Duncombe AS, McMullin MF, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol. 2014;89(6):581–587.
   PubMed Web of Science ®Google Scholar
• Srour SA, Devesa SS, Morton LM, et al. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001–12. Br J Haematol. 2016;174(3):382–396.
   PubMed Web of Science ®Google Scholar
• Deadmond MA, Smith-Gagen JA. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973–2011. J Cancer Res Clin Oncol. 2015;141(12):2131–2138.
   PubMed Web of Science ®Google Scholar
• Mehta J, Wang H, Iqbal SU, et al. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014;55(3):595–600.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895–2901.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Passamonti F, et al. Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol. 2012;30(24):2981–2987.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Parasuraman S, Yu J, et al. Real-world survival among patients with intermediate- to high-risk myelofibrosis in the United States: impact of ruxolitinib approval. Blood. 2020;136(Supplement 1):46–47.
   Google Scholar
• Masarova L, Bose P, Pemmaraju N, et al. Improved survival of patients with myelofibrosis in the last decade. Blood. 2020;136(Supplement 1):50–51.
   PubMedGoogle Scholar
• Selinger HA, Ma X. Jakking up tumor registry reporting of the myeloproliferative neoplasms. Am J Hematol. 2009;84(2):124–126.
   PubMed Web of Science ®Google Scholar
• Surveillance, Epidemiology, and End Results (SEER) Program. What is a cancer registry? [cited Accessed 2021 March 2]. Available from: https://seer.cancer.gov/registries/cancer_registry/index.html
   Google Scholar
• Tiwari RC, Clegg LX, Zou Z. Efficient interval estimation for age-adjusted cancer rates. Stat Methods Med Res. 2006;15(6):547–569.
   PubMed Web of Science ®Google Scholar
• Shallis RM, Wang R, Davidoff A, et al. Epidemiology of the classical myeloproliferative neoplasms: the four corners of an expansive and complex map. Blood Rev. 2020;42:100706.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2017. Bethesda: National Cancer Institute. [cited Accessed 2021 June 11]. https://seer.cancer.gov/csr/1975_2017/
   Google Scholar
• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–951.
   PubMed Web of Science ®Google Scholar
• Maynadie M, Girodon F, Manivet-Janoray I, et al. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France). Haematologica. 2011;96(1):55–61.
   PubMed Web of Science ®Google Scholar
• Hultcrantz M, Ravn Landtblom A, Andreasson B, et al. Incidence of myeloproliferative neoplasms – trends by subgroup and age in a population-based study in Sweden. J Intern Med. 2020;287(4):448–454.
   PubMed Web of Science ®Google Scholar
• Baade PD, Ross DM, Anderson LA, et al. Changing incidence of myeloproliferative neoplasms in Australia, 2003–2014. Am J Hematol. 2019;94(4):E107–E109.
   PubMed Web of Science ®Google Scholar
• Byun JM, Kim YJ, Youk T, et al. Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004–2013. Ann Hematol. 2017;96(3):373–381.
   PubMed Web of Science ®Google Scholar
• Heppner J, Nguyen LT, Guo M, et al. Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada. BMC Res Notes. 2019;12(1):286.
   PubMedGoogle Scholar
• Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15.
   PubMedGoogle Scholar
• Guglielmelli P, Pacilli A, Rotunno G, et al. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood. 2017;129(24):3227–3236.
   PubMed Web of Science ®Google Scholar
• Barosi G, Rosti V, Bonetti E, et al. Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis. PLoS One. 2012;7(4):e35631.
   PubMed Web of Science ®Google Scholar
• JAKAFI® (ruxolitinib). Full Prescribing Information. Wilmington, DE, USA: Incyte Corporation, 2020.
   Google Scholar
• Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426–435.
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787–798.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Harrison C, Cortes JE, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 2015;1(5):643–651.
   PubMed Web of Science ®Google Scholar
• INREBIC® (fedratinib) Full Prescribing Information. Summit, NJ, USA: Celgene Corporation; 2019.
   Google Scholar
• Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30(8):1701–1707.
   PubMed Web of Science ®Google Scholar
• Meckstroth S, Wang R, Ma X, et al. Patterns of care and outcomes among older patients with myelofibrosis: a population-based study. Blood. 2020;136(Supplement 1):21–22.
   Google Scholar
• Thomas JW, Shah MV, Vachhani P, et al. Risk of mortality and leukemic transformation in primary myelofibrosis before and after ruxolitinib approval. Blood. 2020;136(Supplement 1):28–28.
   Google Scholar